Cover Image

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient's perspective shortly (2 to 4 weeks) after initiation...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alice B. Gottlieb (Author), Russel Burge (Author), William N. Malatestinic (Author), Baojin Zhu (Author), Yunyang Zhao (Author), Julie McCormack (Author), Miriam Kimel (Author), Joseph F. Merola (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2023-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023)

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
by: April W. Armstrong, et al.
Published: (2024)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
by: Masaru Honma, et al.
Published: (2020)

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
by: April W. Armstrong, et al.
Published: (2024)

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
by: Alexandra B. Kimball, et al.
Published: (2017)

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial
by: Lyn Guenther, et al.
Published: (2020)

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
by: Mark Lebwohl, et al.
Published: (2024)

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
by: Alexander Egeberg, et al.
Published: (2024)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
by: Jennifer Soung, et al.
Published: (2023)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020)

Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019)

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
by: Lluís Puig, et al.
Published: (2020)

Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis
by: Rui Yuan Xia, et al.
Published: (2023)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017)

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
by: April Armstrong, et al.
Published: (2024)

Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
by: Song B, et al.
Published: (2024)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023)

Development of the neurotrophic keratopathy questionnaire: qualitative research
by: Lindsey T. Murray, et al.
Published: (2020)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
by: Kim Papp, et al.
Published: (2022)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
by: Annunziata Raimondo, MD, et al.
Published: (2021)

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
by: Sebastian Spindeldreher, et al.
Published: (2020)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
by: Craig Leonardi, et al.
Published: (2020)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017)

Monocyte to high-density lipoprotein cholesterol ratio decreased in patients with psoriasis treated with ixekizumab
by: Funda Tamer, et al.
Published: (2023)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016-2021
by: Adam Reich, et al.
Published: (2023)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
by: Saxon D. Smith, et al.
Published: (2023)

Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
by: Lisa Schots, et al.
Published: (2024)

Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis
by: Li Y, et al.
Published: (2024)